Publications by authors named "G Pignot"
Safety and Efficacy of Neoadjuvant Durvalumab Plus Gemcitabine/Cisplatin or Carboplatin in Patients With Operable High-Risk Upper Tract Urothelial Carcinoma: The iNDUCT-GETUG V08 Trial.
J Clin Oncol
February 2025
Purpose: After radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC), prognosis is poor for high-risk patients. This study evaluated safety and efficacy of neoadjuvant chemotherapy (cisplatin or carboplatin + gemcitabine) in combination with durvalumab in these patients.
Patients And Methods: This phase II trial (ClinicalTrials.
The KEYNOTE-564 trial showed that adjuvant immune checkpoint inhibitor (ICI) therapy with pembrolizumab, a PD-1 antibody, significantly improved disease-free survival (DFS) and overall (OS) survival in localised clear-cell renal cell carcinoma (RCC) with a high risk of relapse. The TiNivo and CONTACT-03 trials have reported results for subsequent therapy after progression on ICI therapy in the metastatic setting. The European Association of Urology (EAU) RCC guidelines panel reassessed the new trial results to update recommendations for adjuvant therapy and post-adjuvant therapy.
View Article and Find Full Text PDFPurpose: Immune Checkpoints Inhibitors (ICI) have changed the therapeutic landscape of metastatic renal cell carcinoma first-line treatment with complete response (CR) at metastatic sites observed in 10 to 15% of cases. Delayed nephrectomy could be discussed for patients having a clinical benefit from immunotherapy-based treatment. However, it is unclear whether prior immunotherapy exposure adversely influences the complexity of surgery.
View Article and Find Full Text PDFArticle Synopsis
- Gender differences significantly impact bladder cancer prevalence, with men at higher risk but women often diagnosed later with more advanced disease.
- Women face more challenges with treatment outcomes and experience higher rates of recurrence after certain therapies due to differing immunogenic responses.
- There is a pressing need for more research on sex and gender effects in bladder cancer to bridge gaps in treatment and improve prognoses for women.
Article Synopsis
- Metastatic kidney cancer patients who respond well to immunotherapy are being reconsidered for primary surgery, particularly nephron-sparing surgery, due to their prolonged survival.
- A study analyzed 13 patients who had partial nephrectomy after achieving complete responses to immunotherapy, finding no positive surgical margins and acceptable complication rates.
- Results showed promising renal function and oncological outcomes, indicating that partial nephrectomy is feasible after immunotherapy, but more research is necessary for definitive conclusions.